Biomarkers Associated with the Development of Comorbidities in Patients with Atopic Dermatitis: A Systematic Review

Overview

Journal Allergy

Specialty Allergy & Immunology

Date 2022 Nov 11

PMID 36366871

Authors

Conor Broderick

Stefanie Ziehfreund

Karin van Bart

Bernd Arents

Kilian Eyerich

Stephan Weidinger

Joseph Rastrick

Alexander Zink

Carsten Flohr

Affiliations

Soon will be listed here.

Abstract

Biomarkers associated with the development of comorbidities in atopic dermatitis (AD) patients have been reported, but have not yet been systematically reviewed. Seven electronic databases were searched, from database inception to September 2021. English language randomized controlled trials, prospective and retrospective cohort, and case-control studies that investigated the association between a biomarker and the development of comorbidities in AD patients were included. Two authors independently screened the records for eligibility, one extracted all data, and critically appraised the quality of studies and risk of bias. Fifty six articles met the inclusion criteria, evaluating 146 candidate biomarkers. The most frequently reported biomarkers were filaggrin mutations and allergen specific-IgE. Promising biomarkers include specific-IgE and/or skin prick tests predicting the development of asthma, and genetic polymorphisms predicting the occurrence of eczema herpeticum. The identified studies and biomarkers were highly heterogeneous, and associated with predominately moderate-to-high risk of bias across multiple domains. Overall, findings were inconsistent. High-quality studies assessing biomarkers associated with the development of comorbidities in people with AD are lacking. Harmonized datasets and independent validation studies are urgently needed.

Citing Articles

Predictive biomarker for allergic March in children using blood proteomics.

Kang M, Kwak D, Park H, Kim H, Yeom J, Lee S Pediatr Pulmonol. 2024; 60(1):e27349.

PMID: 39470001 PMC: 11740652. DOI: 10.1002/ppul.27349.

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches.

Chaudhary F, Lee W, Escander T, Agrawal D J Biotechnol Biomed. 2024; 7(3):314-328.

PMID: 39119011 PMC: 11309089. DOI: 10.26502/jbb.2642-91280155.

Tape Stripping - Searching for Minimally Invasive Biomarkers in Atopic Dermatitis.

Zysk W, Trzeciak M Dermatol Pract Concept. 2024; 14(2).

PMID: 38810072 PMC: 11135974. DOI: 10.5826/dpc.1402a123.

Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective.

Ramessur R, Dand N, Langan S, Saklatvala J, Fritzsche M, Holland S Br J Dermatol. 2024; 191(1):14-23.

PMID: 38419411 PMC: 11188926. DOI: 10.1093/bjd/ljae080.

Atopic March or Atopic Multimorbidity-Overview of Current Research.

Mrkic Kobal I, Plavec D, Vlasic Loncaric Z, Jerkovic I, Turkalj M Medicina (Kaunas). 2024; 60(1).

PMID: 38256282 PMC: 10819021. DOI: 10.3390/medicina60010021.

References

Cosickic A, Skokic F, Selimovic A, Mulic M, Suljendic S, Dedic N . Development of Respiratory Allergies, Asthma and Allergic Rhinits in Children with Atopic Dermatitis. Acta Clin Croat. 2018; 56(2):308-317. DOI: 10.20471/acc.2017.56.02.15. View

Potaczek D, Nastalek M, Okumura K, Wojas-Pelc A, Undas A, Nishiyama C . An association of TLR2–16934A >T polymorphism and severity/phenotype of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010; 25(6):715-21. DOI: 10.1111/j.1468-3083.2010.03812.x. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Glickman J, Han J, Garcet S, Krueger J, Pavel A, Guttman-Yassky E . Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. J Allergy Clin Immunol Pract. 2020; 8(10):3622-3625.e19. DOI: 10.1016/j.jaip.2020.07.015. View

Howell M, Gao P, Kim B, Lesley L, Streib J, Taylor P . The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011; 128(5):1006-14. PMC: 3205328. DOI: 10.1016/j.jaci.2011.06.003. View

Filipiak-Pittroff B, Schnopp C, Berdel D, Naumann A, Sedlmeier S, Onken A . Predictive value of food sensitization and filaggrin mutations in children with eczema. J Allergy Clin Immunol. 2011; 128(6):1235-1241.e5. DOI: 10.1016/j.jaci.2011.09.014. View

Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M . Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol. 2006; 55(5):765-71. DOI: 10.1016/j.jaad.2006.04.064. View

Margolis D, Kim B, Apter A, Gupta J, Hoffstad O, Papadopoulos M . Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis. JAMA Dermatol. 2014; 150(3):254-9. PMC: 4414492. DOI: 10.1001/jamadermatol.2013.7954. View

Zink A, Arents B, Fink-Wagner A, Seitz I, Mensing U, Wettemann N . Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries. Acta Derm Venereol. 2018; 99(3):263-267. DOI: 10.2340/00015555-3102. View

10.

Thyssen J, Carlsen B, Menne T, Linneberg A, Nielsen N, Meldgaard M . Filaggrin null mutations increase the risk and persistence of hand eczema in subjects with atopic dermatitis: results from a general population study. Br J Dermatol. 2010; 163(1):115-20. DOI: 10.1111/j.1365-2133.2010.09822.x. View

11.

Lee S, Wang H, Kim E, Hwang H, Choi E, Lee H . Clinical characteristics and genetic variation in atopic dermatitis patients with and without allergic contact dermatitis. Eur J Dermatol. 2018; 28(5):637-643. DOI: 10.1684/ejd.2018.3422. View

12.

Chang J, Mitra N, Hoffstad O, Margolis D . Association of Filaggrin Loss of Function and Thymic Stromal Lymphopoietin Variation With Treatment Use in Pediatric Atopic Dermatitis. JAMA Dermatol. 2016; 153(3):275-281. DOI: 10.1001/jamadermatol.2016.4467. View

13.

Hackler 3rd E, Lew J, Gore M, Ayers C, Atzler D, Khera A . Racial Differences in Cardiovascular Biomarkers in the General Population. J Am Heart Assoc. 2019; 8(18):e012729. PMC: 6817997. DOI: 10.1161/JAHA.119.012729. View

14.

Xie Q, Dai X, Tang X, Chan C, Chan C . Risk of Mental Disorders in Children and Adolescents With Atopic Dermatitis: A Systematic Review and Meta-Analysis. Front Psychol. 2019; 10:1773. PMC: 6691144. DOI: 10.3389/fpsyg.2019.01773. View

15.

Ezzedine K, Droitcourt C, Ged C, Diallo A, Hubiche T, de Verneuil H . Usefulness of a global clinical ichthyosis vulgaris scoring system for predicting common FLG null mutations in an adult caucasian population. Br J Dermatol. 2012; 167(5):1165-9. DOI: 10.1111/j.1365-2133.2012.11062.x. View

16.

Marenholz I, Kerscher T, Bauerfeind A, Esparza-Gordillo J, Nickel R, Keil T . An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol. 2009; 123(4):911-6. DOI: 10.1016/j.jaci.2009.01.051. View

17.

Kaufman B, Guttman-Yassky E, F Alexis A . Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018; 27(4):340-357. DOI: 10.1111/exd.13514. View

18.

Wang I, Lin T, Kuo C, Lin S, Lee Y, Chen P . Filaggrin polymorphism P478S, IgE level, and atopic phenotypes. Br J Dermatol. 2011; 164(4):791-6. DOI: 10.1111/j.1365-2133.2011.10212.x. View

19.

Ring J, Zink A, Arents B, Seitz I, Mensing U, Schielein M . Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019; 33(7):1331-1340. DOI: 10.1111/jdv.15634. View

20.

Gustafsson D, Sjoberg O, Foucard T . Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age. Allergy. 2001; 55(3):240-5. DOI: 10.1034/j.1398-9995.2000.00391.x. View